EGFR and non-small cell lung carcinoma: The study demonstrated that anlotinib, when added onto EGFR TKI therapy following gradual progression or oligo-progression, conferred significant PFS benefits upon EGFR mutant NSCLC patients, adding to the growing evidence on the choice of anlotinib as an effective treatment after gradual progression or oligoprogression while patients are receiving first-line EGFR TKI therapy.